Tags

Type your tag names separated by a space and hit enter

Moxifloxacin: a respiratory fluoroquinolone.
Expert Opin Pharmacother. 2008 Jul; 9(10):1755-72.EO

Abstract

BACKGROUND

Respiratory quinolones are a class of antimicrobials with a high activity against most respiratory pathogens. Moxifloxacin is a fourth-generation fluoroquinolone that has been shown to be effective against Gram-positive, Gram-negative, and atypical strains, as well as multi-drug resistant Streptococcus pneumoniae.

OBJECTIVE

To review and update the clinical efficacy of moxifloxacin in the treatment of respiratory infections.

METHOD

To perform a systematic review of publications on the clinical efficacy of moxifloxacin in respiratory infections.

RESULTS

The clinical efficacy of moxifloxacin has been shown in controlled studies of community-acquired pneumonia, exacerbations of chronic bronchitis and acute bacterial rhinosinusitis. Moxifloxacin has demonstrated a faster resolution of symptoms in community-acquired pneumonia and exacerbations of chronic bronchitis patients compared with first-line therapy together with excellent eradication rates.

CONCLUSIONS

The use of moxifloxacin as first-line therapy for moderate to severe respiratory infections in the community and the hospital has been recognized in international guidelines.

Authors+Show Affiliations

Servei de Pneumologia, Institut Clínic del Tòrax (IDIBAPS), Ciber de Enfermedades Respiratorias (CIBERES), Hospital Clínic, Barcelona, Spain. marcm@clinic.ub.esNo affiliation info available

Pub Type(s)

Journal Article
Review
Systematic Review

Language

eng

PubMed ID

18570608

Citation

Miravitlles, Marc, and Antonio Anzueto. "Moxifloxacin: a Respiratory Fluoroquinolone." Expert Opinion On Pharmacotherapy, vol. 9, no. 10, 2008, pp. 1755-72.
Miravitlles M, Anzueto A. Moxifloxacin: a respiratory fluoroquinolone. Expert Opin Pharmacother. 2008;9(10):1755-72.
Miravitlles, M., & Anzueto, A. (2008). Moxifloxacin: a respiratory fluoroquinolone. Expert Opinion On Pharmacotherapy, 9(10), 1755-72. https://doi.org/10.1517/14656566.9.10.1755
Miravitlles M, Anzueto A. Moxifloxacin: a Respiratory Fluoroquinolone. Expert Opin Pharmacother. 2008;9(10):1755-72. PubMed PMID: 18570608.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Moxifloxacin: a respiratory fluoroquinolone. AU - Miravitlles,Marc, AU - Anzueto,Antonio, PY - 2008/6/24/pubmed PY - 2008/8/12/medline PY - 2008/6/24/entrez SP - 1755 EP - 72 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 9 IS - 10 N2 - BACKGROUND: Respiratory quinolones are a class of antimicrobials with a high activity against most respiratory pathogens. Moxifloxacin is a fourth-generation fluoroquinolone that has been shown to be effective against Gram-positive, Gram-negative, and atypical strains, as well as multi-drug resistant Streptococcus pneumoniae. OBJECTIVE: To review and update the clinical efficacy of moxifloxacin in the treatment of respiratory infections. METHOD: To perform a systematic review of publications on the clinical efficacy of moxifloxacin in respiratory infections. RESULTS: The clinical efficacy of moxifloxacin has been shown in controlled studies of community-acquired pneumonia, exacerbations of chronic bronchitis and acute bacterial rhinosinusitis. Moxifloxacin has demonstrated a faster resolution of symptoms in community-acquired pneumonia and exacerbations of chronic bronchitis patients compared with first-line therapy together with excellent eradication rates. CONCLUSIONS: The use of moxifloxacin as first-line therapy for moderate to severe respiratory infections in the community and the hospital has been recognized in international guidelines. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/18570608/Moxifloxacin:_a_respiratory_fluoroquinolone_ L2 - https://www.tandfonline.com/doi/full/10.1517/14656566.9.10.1755 DB - PRIME DP - Unbound Medicine ER -